Pfizer Inc. today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results